Stanford University
Showing 21-40 of 98 Results
-
Bo Wang
Assistant Professor of Bioengineering and, by courtesy, Developmental Biology
Current Research and Scholarly InterestsResearch interests:
(1) Systems biology of whole-body regeneration
(2) Cell type evolution through the lens of single-cell multiomic sequencing analysis
(3) Quantitative biology of brain regeneration
(4) Regeneration of animal-algal photosymbiotic systems -
C. Jason Wang, MD, PhD
LCY: Tan Lan Lee Professor and Professor of Pediatrics (General Pediatrics) and of Health Policy
BioDr. Wang is the Director of Center for Policy, Outcomes and Prevention. Prior to coming to Stanford in 2011, he was a faculty member at Boston University Schools of Medicine and Public Health. His other professional experiences include working as a management consultant with McKinsey and Company and serving as the project manager for Taiwan's National Health Insurance Reform Task-force. His current interests include: 1) COVID-19 related policies; 2) developing tools for assessing and improving the value of healthcare; 3) facilitating the use of mobile technology in improving quality of care; 4) supporting competency-based medical education curriculum, and 5) engaging in healthcare delivery and payment reforms.
-
Ge Wang
Associate Professor of Music, Senior Fellow at the Stanford Institute for HAI and Associate Professor, by courtesy, of Computer Science
BioGe Wang is an Associate Professor at Stanford University in the Center for Computer Research in Music and Acoustics (CCRMA). He specializes in the art of design and computer music — researching programming languages and interactive software design for music, interaction design, mobile music, laptop orchestras, expressive design of virtual reality, aesthetics of music technology design, and education at the intersection of computer science and music. Ge is the author of the ChucK music programming language, the founding director of the Stanford Laptop Orchestra (SLOrk). Ge is also the Co-founder of Smule (reaching over 200 million users), and the designer of the iPhone's Ocarina and Magic Piano. Ge is a 2016 Guggenheim Fellow, and the author of ARTFUL DESIGN: TECHNOLOGY IN SEARCH OF THE SUBLIME—a book on design and technology, art and life‚ published by Stanford University Press in 2018 (see https://artful.design/)
-
Paul J. Wang, MD
John R. and Ai Giak L. Singleton Director, Professor of Medicine (Cardiovascular Medicine) and, by courtesy, of Bioengineering
Current Research and Scholarly InterestsDr. Wang's research centers on the development of innovative approaches to the treatment of arrhythmias, including more effective catheter ablation techniques, more reliable implantable devices, and less invasive treatments. Dr. Wang's clinical research interests include atrial fibrillation, ventricular tachycardia, syncope, and hypertrophic cardiomyopathy. Dr. Wang is committed to addressing disparities in care and is actively involved in increasing diversity in clinical trials.
-
Shan X. Wang
Leland T. Edwards Professor in the School of Engineering and Professor of Electrical Engineering and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)
Current Research and Scholarly InterestsShan Wang was named the Leland T. Edwards Professor in the School of Engineering in 2018. He directs the Center for Magnetic Nanotechnology and is a leading expert in biosensors, information storage and spintronics. His research and inventions span across a variety of areas including magnetic biochips, in vitro diagnostics, cancer biomarkers, magnetic nanoparticles, magnetic sensors, magnetoresistive random access memory, and magnetic integrated inductors.
-
Sui Wang, PhD
Assistant Professor of Ophthalmology
Current Research and Scholarly InterestsOur research focuses on unraveling the molecular mechanisms underlying retinal development and diseases. We employ genetic and genomic tools to explore how various retinal cell types, including neurons, glia, and the vasculature, respond to developmental cues and disease insults at the epigenomic and transcriptional levels. In addition, we investigate their interactions and collective contributions to maintain retinal integrity.
1. Investigating retinal development:
We utilize genetic tools and methods such as in vivo plasmid electroporation and CRISPR to dissect the roles of cis-regulatory elements and transcription factors in controlling retinal development.
2. Understanding diabetes-induced cell-type-specific responses in the retina:
Diabetes triggers a range of multicellular responses in the retina, such as vascular lesions, glial dysfunction, and neurodegeneration, all of which contribute to retinopathy. We delve into the detailed molecular mechanisms underlying these diabetes-induced cell-type-specific responses and the pathogenesis of diabetic retinopathy.
3. Developing molecular tools for labeling and manipulation of specific cell types in vivo:
Cis-regulatory elements, particularly enhancers, play pivotal roles in directing tissue- and cell-type-specific expression. Our interest lies in identifying enhancers that can drive cell type-specific expression in the retina and brain. We incorporate these enhancers into plasmid or AAV-based delivery systems, enabling precise labeling and manipulation of specific cell types in vivo. -
Taia T. Wang, MD, PhD, MSCI
Assistant Professor of Medicine (Infectious Diseases) and of Microbiology and Immunology
Current Research and Scholarly InterestsLaboratory of Mechanisms in Human Immunity and Disease Pathogenesis
Antibodies are a critical component of host defense. While the importance of humoral immunity has been recognized for decades, substantial gaps in knowledge remain around how antibodies function, and how their function is regulated, in vivo. Our laboratory performs studies designed to fill in these gaps, with the goal of enabling new vaccine and therapeutic strategies to prevent human disease. My interest in this area culminated from training in medicine, RNA virus biology (PhD), and molecular antibody biology (postdoctoral training). The intersection of these topics, viral immunity and disease pathogenesis, is the focus of our work. The essential question driving our research is why a small subset of people develop severe or fatal disease during viral infection while most infections result in a subclinical or mild outcome, even in at-risk populations. Our hypothesis is that the antibody signaling pathways that are engaged during viral infection through Fc gamma receptors (FcγRs) are a key driver of these distinct outcomes. We are focused on several major unknowns to address this hypothesis: How are antibody effector functions regulated in vivo and does this change in disease? How do distinct signaling pathways engaged by IgG immune complex-FcγR interactions impact host cell genetic regulation and the ultimate inflammatory/immune response? What are the tissue-specific functions that antibodies engage? How does the heterogeneity in post-translational modifications (PTMs) of human antibodies contribute to heterogeneity in viral immunity?
Current clinical studies:
Recruiting:
An Open Label Study of IgG Fc Glycan Composition in Human Immunity
Principal Investigator: Taia T. Wang, MD, PhD
ClinicalTrials.gov Identifier:
NCT01967238 -
Xinnan Wang
Associate Professor of Neurosurgery
Current Research and Scholarly InterestsMechanisms underlying mitochondrial dynamics and function, and their implications in neurological disorders.
-
Zhecheng Wang
Postdoctoral Scholar, Civil and Environmental Engineering
BioI am a HAI (Human-Centered AI) Postdoctoral Fellow at Stanford University. Here is my website: https://wangzhecheng.github.io
-
Victoria Ward
Clinical Associate Professor, Pediatrics
Current Research and Scholarly InterestsGlobal child health, digital health, preterm birth, human trafficking
-
Robert Waymouth
Robert Eckles Swain Professor of Chemistry and Professor, by courtesy, of Chemical Engineering
BioRobert Eckles Swain Professor in Chemistry Robert Waymouth investigates new catalytic strategies to create useful new molecules, including bioactive polymers, synthetic fuels, and sustainable plastics. In one such breakthrough, Professor Waymouth and Professor Wender developed a new class of gene delivery agents.
Born in 1960 in Warner Robins, Georgia, Robert Waymouth studied chemistry and mathematics at Washington and Lee University in Lexington, Virginia (B.S. and B.A., respectively, both summa cum laude, 1982). He developed an interest in synthetic and mechanistic organometallic chemistry during his doctoral studies in chemistry at the California Institute of Technology under Professor R.H. Grubbs (Ph.D., 1987). His postdoctoral research with Professor Piero Pino at the Institut fur Polymere, ETH Zurich, Switzerland, focused on catalytic hydrogenation with chiral metallocene catalysts. He joined the Stanford University faculty as assistant professor in 1988, becoming full professor in 1997 and in 2000 the Robert Eckles Swain Professor of Chemistry.
Today, the Waymouth Group applies mechanistic principles to develop new concepts in catalysis, with particular focus on the development of organometallic and organic catalysts for the synthesis of complex macromolecular architectures. In organometallic catalysis, the group devised a highly selective alcohol oxidation catalyst that selectively oxidizes unprotected polyols and carbohydrates to alpha-hyroxyketones. In collaboration with Dr. James Hedrick of IBM, we have developed a platform of highly active organic catalysts and continuous flow reactors that provide access to polymer architectures that are difficult to access by conventional approaches.
The Waymouth group has devised selective organocatalytic strategies for the synthesis of functional degradable polymers and oligomers that function as "molecular transporters" to deliver genes, drugs and probes into cells and live animals. These advances led to the joint discovery with the Wender group of a general, safe, and remarkably effective concept for RNA delivery based on a new class of synthetic cationic materials, Charge-Altering Releasable Transporters (CARTs). This technology has been shown to be effective for mRNA based cancer vaccines.
